Organon & Co. (OGN)
Organon & Co. develops and delivers health solutions, focusing on women's health, biosimilars, and established brands. The company operates globally, selling primarily to wholesalers, retailers, hospitals, government agencies, and managed health care providers.
Company Overview
Organon & Co. delivers diverse health solutions, including women's health, biosimilars, and established brands, offering a compelling investment opportunity through its global reach, a 4.14% dividend yield, and a low P/E ratio of 4.26, positioning it as a value stock in the healthcare sector.
Investment Thesis
Organon & Co. presents a compelling investment opportunity due to its diverse portfolio of established pharmaceutical products and focus on high-growth areas like women's health and biosimilars. The company's attractive dividend yield of 4.14% and low P/E ratio of 4.26 suggest it may be undervalued relative to its peers. Growth catalysts include expanding its biosimilars offerings and increasing market penetration in women's health products. With a solid gross margin of 55.0%, Organon demonstrates efficient operations. The company's established distribution network and global presence provide a strong foundation for future growth, making it an attractive option for value-oriented investors seeking stable income and long-term appreciation.
Key Highlights
- Market capitalization of $2.13 billion, indicating a mid-sized player in the pharmaceutical industry.
- P/E ratio of 4.26, suggesting the company may be undervalued compared to its earnings.
- Profit margin of 8.0%, reflecting the company's ability to generate profit from its revenue.
- Gross margin of 55.0%, demonstrating efficient cost management in its operations.
- Dividend yield of 4.14%, offering an attractive income stream for investors.
Competitors
Strengths
- Diverse product portfolio across multiple therapeutic areas.
- Strong presence in women's health and biosimilars.
- Global distribution network.
- Attractive dividend yield.
Weaknesses
- Dependence on established brands with potential for generic competition.
- Relatively low profit margin compared to some peers.
- Limited pipeline of innovative new products.
- High debt levels from spin-off.
Catalysts
- Upcoming: Potential FDA approvals for new biosimilar products in the next 12-18 months.
- Ongoing: Expansion of the women's health portfolio through strategic partnerships.
- Ongoing: Increasing market penetration in emerging markets, driving revenue growth.
- Ongoing: Cost optimization initiatives improving profit margins.
Risks
- Potential: Loss of patent protection for key products, leading to generic competition.
- Potential: Regulatory setbacks or delays in product approvals.
- Ongoing: Pricing pressures from healthcare providers and government agencies.
- Ongoing: Economic downturns affecting consumer spending on healthcare.
- Ongoing: Product liability claims and litigation.
Growth Opportunities
- Expanding the biosimilars portfolio: The global biosimilars market is projected to reach $100 billion by 2025. Organon can capitalize on this growth by developing and launching new biosimilar products, particularly in immunology and oncology, leveraging its existing infrastructure and expertise. This expansion can significantly boost revenue and market share over the next 3-5 years.
- Increasing penetration in women's health: The women's health market is experiencing increased attention and investment. Organon can further penetrate this market by expanding the reach of its contraception and fertility brands, such as Nexplanon/Implanon. Focusing on emerging markets and strategic partnerships can drive significant growth in this segment over the next 2-3 years.
- Strategic acquisitions and partnerships: Organon can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. Targeting companies with complementary products or technologies can accelerate growth and enhance its competitive position. This strategy can be implemented within the next 1-2 years to drive long-term value.
- Leveraging established brands: Organon has a portfolio of established brands across various therapeutic areas, including cardiovascular, respiratory, and dermatology. By investing in marketing and product innovation for these brands, the company can maintain market share and generate stable revenue streams. This ongoing effort will support consistent performance.
- Geographic expansion into emerging markets: Emerging markets offer significant growth opportunities due to increasing healthcare spending and unmet medical needs. Organon can expand its presence in these markets by establishing local partnerships and tailoring its product offerings to meet local needs. This expansion can contribute to long-term revenue growth over the next 3-5 years.
Opportunities
- Expansion of biosimilars portfolio.
- Increased penetration in emerging markets.
- Strategic acquisitions and partnerships.
- Growing demand for women's health products.
Threats
- Increasing competition from generic and biosimilar manufacturers.
- Pricing pressures and regulatory changes.
- Product liability and patent litigation.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Established brand portfolio with recognized names.
- Global distribution network providing access to diverse markets.
- Expertise in biosimilar development and manufacturing.
- Focus on women's health, a growing and underserved market.
About
Organon & Co. was incorporated in 2020 and is headquartered in Jersey City, New Jersey. The company develops and delivers a wide range of health solutions through its portfolio of prescription therapies, operating both in the United States and internationally. Organon's business is segmented into key areas, with a strong focus on women's health, offering products like Nexplanon/Implanon for contraception and fertility. The biosimilars portfolio includes immunology products such as Brenzys, Renflexis, and Hadlima, along with oncology products like Ontruzant and Aybintio. Additionally, Organon provides cardiovascular products under brands like Zetia and Vytorin, respiratory treatments such as Singulair and Dulera, and dermatology products like Diprosone and Elocon. The company also offers solutions for bone health (Fosamax), non-opioid pain management (Arcoxia), and treatments for benign prostatic hyperplasia (Proscar) and male pattern hair loss (Propecia). Organon distributes its products through various channels, including drug wholesalers, retailers, hospitals, government agencies, and managed health care providers.
What They Do
- Develops and delivers health solutions globally.
- Offers prescription therapies in various therapeutic areas.
- Focuses on women's health products, including contraception and fertility solutions.
- Provides biosimilars for immunology and oncology treatments.
- Offers cardiovascular products for cholesterol management and hypertension.
- Provides respiratory products for asthma and allergic rhinitis.
- Offers dermatology and bone health products.
Business Model
- Develops and manufactures prescription therapies.
- Sells products to drug wholesalers, retailers, and hospitals.
- Distributes products through government agencies and managed health care providers.
- Generates revenue through product sales and licensing agreements.
Industry Context
Organon & Co. operates within the global drug manufacturing industry, which is characterized by intense competition and evolving market dynamics. The industry is witnessing growth in biosimilars and increasing demand for women's health products. Organon's focus on these areas positions it favorably within the market. The company competes with both large pharmaceutical companies and smaller, specialized players. Trends include increasing regulatory scrutiny, pricing pressures, and the need for continuous innovation. Organon's established brand portfolio and global distribution network provide a competitive edge in this landscape.
Key Customers
- Drug wholesalers and retailers
- Hospitals and healthcare systems
- Government agencies
- Managed health care providers (HMOs, PBMs)
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.51B | -$205M | $0.00 |
| Q3 2025 | $1.60B | $0 | $0.00 |
| Q2 2025 | $1.59B | $0 | $0.00 |
| Q1 2025 | $1.51B | $0 | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Organon & Co. (OGN) stock price: $7.44 (+0.20, +2.76%)
Latest News
-
Earnings Scheduled For February 12, 2026
benzinga · Feb 12, 2026
Technical Analysis
Rationale
AI-generated technical analysis for OGN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Organon & Co. (OGN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for OGN.
Make a Prediction
Set your price target for Organon & Co. (OGN), choose a timeframe, and track your prediction accuracy.
Current price: $7.44
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OGN.
Price Targets
Wall Street price target analysis for OGN.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -2.9% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 8/100
Gross margin at 53.6% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 8/100
Strong cash reserves of $574M provide a solid financial cushion for growth investments and market downturns.
-
R&D Intensity 5/100
R&D spending at 5.9% of revenue is moderate, balancing current profitability with future development.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 1.93% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates OGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Organon & Co. do?
Organon & Co. is a global healthcare company that develops and delivers a diverse range of health solutions, with a focus on women's health, biosimilars, and established pharmaceutical brands. The company offers prescription therapies across various therapeutic areas, including contraception, fertility, immunology, oncology, cardiovascular, respiratory, dermatology, and bone health. Organon sells its products through a global distribution network to drug wholesalers, retailers, hospitals, government agencies, and managed health care providers, aiming to address unmet medical needs and improve patient outcomes worldwide.
Is OGN stock a good buy?
OGN stock presents a mixed picture for investors. Its low P/E ratio of 4.26 and attractive dividend yield of 4.14% suggest potential undervaluation and income generation. The company's focus on women's health and biosimilars offers growth opportunities. However, investors should consider the company's debt levels, reliance on established brands, and competitive pressures. A balanced approach, considering both the value proposition and potential risks, is crucial before investing in OGN.
What are the main risks for OGN?
Organon faces several key risks, including increasing competition from generic and biosimilar manufacturers, which could erode market share and revenue. Pricing pressures from healthcare providers and regulatory changes also pose a threat to profitability. Additionally, the company is exposed to product liability claims and patent litigation, which could result in significant financial losses. Economic downturns could affect consumer spending on healthcare, impacting sales. Managing these risks effectively is crucial for Organon's long-term success.
Is OGN a good stock to buy?
Whether OGN is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the OGN MoonshotScore?
The MoonshotScore for OGN is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is OGN data updated?
OGN stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to OGN is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for OGN?
Growth catalysts for Organon & Co. (OGN) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Organon & Co.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are OGN's main competitors?
Organon & Co. (OGN) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether OGN has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about OGN?
Wall Street analyst coverage for OGN includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is OGN's market cap?
Market capitalization (market cap) for OGN is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows OGN's current market cap alongside enterprise value and other valuation metrics.
How has OGN stock performed recently?
OGN's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing OGN's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in OGN?
Key risk categories for OGN include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures OGN's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling OGN?
Insider trading activity for OGN tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is OGN a good stock for beginners?
Organon & Co. (OGN) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is OGN for first-time investors?
Every stock carries risk, including Organon & Co. (OGN). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like OGN.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial situation.